Disease · MONDO_0006964

secondary hyperparathyroidism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. secondary hyperparathyroidism. Diseases, record MONDO_0006964. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006964

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: secondary hyperparathyroidism; Open Targets
Open Targets ID: MONDO_0006964; Open Targets
Other names: Hyperparathyroidism, Secondary, secondary hyperparathyroidism (disease), secondary hyperparathyroidism (disorder), secondary hyperparathyroidism NOS; Open Targets
Disease Ontology: DOID:12466; Disease Ontology
MeSH: D006962; MeSH
NCI Thesaurus: C113335; NCI Thesaurus
Highest stage of its drugs: Approval, for 8 of its 26 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CINACALCET	CHEMBL1201284	Small molecule	Approval	EMA Human Drugs	35	34	34	Drugs and targets
PARICALCITOL	CHEMBL1200622	Small molecule	Approval	DailyMed	31	26	26	Drugs and targets
ETELCALCETIDE	CHEMBL3545184	Protein	Approval	EMA Human Drugs, FDA and TTD	18	15	15	Drugs and targets
DOXERCALCIFEROL	CHEMBL1200810	Small molecule	Approval	DailyMed	11	8	8	Drugs and targets
EVOCALCET	CHEMBL4297621	Small molecule	Approval	PMDA	8	7	7	Drugs and targets
CINACALCET HYDROCHLORIDE	CHEMBL1200776	Small molecule	Approval	DailyMed and PMDA	10	6	6	Drugs and targets
CALCIFEDIOL	CHEMBL3544909	Small molecule	Approval	FDA	7	6	6	Drugs and targets
ETELCALCETIDE HYDROCHLORIDE	CHEMBL3545183	Protein	Approval	DailyMed and PMDA	3	1	1	Drugs and targets
CALCITRIOL	CHEMBL846	Small molecule	Phase 3	ClinicalTrials.gov	9	9	8	Drugs and targets
UPACICALCET	CHEMBL6068421	Small molecule	Phase 3	ClinicalTrials.gov	6	5	5	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VDR	Vitamin D3 receptor	9	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
CASR	Extracellular calcium-sensing receptor	6	Calcium sensing receptor agonist; Calcium sensing receptor positive allosteric modulator	Approval	https://conductscience.org/library/genes/846	Drugs and targets

Trials112

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02102204	Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis	Phase 3	902	2017-11-17	Hyperparathyroidism, Secondary	ETELCALCETIDE	Its record names the disease	ClinicalTrials.gov
NCT01785875	Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis	Phase 3	891	2017-03-27	Hyperparathyroidism, Secondary	ETELCALCETIDE	Its record names the disease	ClinicalTrials.gov
NCT01896232	Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet	Phase 3	683	2017-02-08	Secondary Hyperparathyroidism, Chronic Kidney Disease	CINACALCET, ETELCALCETIDE	Its record names the disease	ClinicalTrials.gov
NCT03299244	Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)	Phase 3	637	2021-04-30	Secondary Hyperparathyroidism, Chronic Kidney Disease	CINACALCET HYDROCHLORIDE, ETELCALCETIDE	Its record names the disease	ClinicalTrials.gov
NCT00110890	A Research Study for Patients With End-Stage Renal Disease (ESRD)	Phase 4	552	2011-03-07	End Stage Renal Disease	CINACALCET	Its record names the disease	ClinicalTrials.gov
NCT01788046	Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis	Phase 3	515	2017-03-27	Hyperparathyroidism, Secondary	ETELCALCETIDE	Its record names the disease	ClinicalTrials.gov
NCT01785849	Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis	Phase 3	508	2017-03-27	Hyperparathyroidism, Secondary	ETELCALCETIDE	Its record names the disease	ClinicalTrials.gov
NCT00379899	ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4	360	2010-10-27	Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification, Calcification, Cardiovascular Disease, Chronic Renal Failure, Hyperparathyroidism, Kidney Disease, Nephrology, Secondary Hyperparathyroidism	CINACALCET	Its record names the disease	ClinicalTrials.gov
NCT02282813	Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002	Phase 3	298	2016-08-17	Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency	CALCITRIOL, DOXERCALCIFEROL, PARICALCITOL	Its record names the disease	ClinicalTrials.gov
NCT01341782	Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism	Phase 3	255	2013-06-06	Secondary Hyperparathyroidism, Hemodialysis	MAXACALCITOL, PARICALCITOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 112

See all 112 trials

Comparisons in its trials50

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cinacalcet vs Etelcalcetide: serious adverse events	93 of 341	85 of 338	679	NCT01896232	Trial comparisons
Cinacalcet vs Etelcalcetide: deaths from any cause	9 of 317	4 of 320	637	NCT03299244	Trial comparisons
Cinacalcet vs Etelcalcetide: Number of Participants With Treatment-emergent Symptomatic Hypocalcemia During the Study	15 of 315	35 of 318	633	NCT03299244	Trial comparisons
Cinacalcet vs Etelcalcetide: serious adverse events	61 of 315	53 of 318	633	NCT03299244	Trial comparisons
Cinacalcet vs Etelcalcetide: Number of Participants With cCa < 7.5 mg/dL At Any Time During the Study	61 of 310	109 of 317	627	NCT03299244	Trial comparisons
Cinacalcet vs Etelcalcetide: Number of Participants With cCa < 8.0 mg/dL At Any Time During the Study	194 of 310	241 of 317	627	NCT03299244	Trial comparisons
Cinacalcet vs Etelcalcetide: Number of Participants With cCa < 8.3 mg/dL At Any Time During the Study	245 of 310	273 of 317	627	NCT03299244	Trial comparisons
Cinacalcet vs Standard of Care: Number of Participants With Mean Serum Ca < 9.5 mg/dL	281 of 368	61 of 184	552	NCT00110890	Trial comparisons
Cinacalcet vs Standard of Care: Number of Participants With Mean Serum P < 5.5 mg/dL	231 of 368	92 of 184	552	NCT00110890	Trial comparisons
Cinacalcet vs Standard of Care: Number of Participants With Mean Ca x P < 55 mg^2/dL^2	282 of 368	106 of 184	552	NCT00110890	Trial comparisons

1 to 10 of 50

See all 50 comparisons in its trials

Papers from its trials43

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28332096	RESULT	1	PubMed
25498379	RESULT	1	PubMed
22118402	RESULT	1	PubMed
20056760	RESULT	1	PubMed
19696213	RESULT	1	PubMed
19365139	RESULT	1	PubMed
19110359	RESULT	1	PubMed
18793528	RESULT	1	PubMed
18397701	RESULT	1	PubMed
18310602	RESULT	1	PubMed

1 to 10 of 43

See all 43 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006964

GET https://conductscience.org/api/diseases/v1/MONDO_0006964/drugs?page=2

API reference For AI assistants